Poor
Not Aligned
Patient Risk:
High
Summary
Only contraception and some embryo-fetal risk concepts are supported by the provided label text; many detailed pregnancy/teratogenicity and boxed-warning claims cannot be verified from the supplied label sections, and the boxed-warning status is unverified, preventing reliable on-label alignment assessment.
Category Scores
Accurate Statements
The FDA label for lurbinectedin advises women of childbearing potential to use effective contraception during treatment and for 7 months after the last dose.
5.5 Embryo-Fetal Toxicity; 8.3 Females and Males of Reproductive Potential
The FDA label for lurbinectedin advises men with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose.
5.5 Embryo-Fetal Toxicity; 8.3 Females and Males of Reproductive Potential
In a mechanism-of-action context, lurbinectedin binds DNA in the minor groove and forms adducts that perturb cell cycle activity and lead to cell death.
12.1 Mechanism of Action
Unsupported Statements
Lurbinectedin crosses the placenta and directly affects developing tissues.
Not supported by the provided label excerpts (pregnancy sections advise fetal harm risk but do not explicitly state placental crossing/direct effect).
In animal studies, lurbinectedin binds DNA minor grooves and inhibits transcription.
Minor-groove DNA binding is supported, but transcription inhibition is not explicitly stated in the provided label text.
In animal studies, lurbinectedin disrupts cell division during the embryonic stage.
The provided label text does not mention embryonic-stage cell division disruption.
In rats and rabbits, exposure during organogenesis produced skeletal malformations.
The provided label excerpts do not include rabbit data or a malformation inventory.
In rats and rabbits, exposure during organogenesis produced soft tissue anomalies.
The provided label excerpts do not include rabbit data or a malformation inventory.
In rats and rabbits, external malformations from lurbinectedin exposure included cleft palate.
Not present in the provided label excerpts.
In rats and rabbits, external malformations from lurbinectedin exposure included microphthalmia.
Not present in the provided label excerpts.
In rats and rabbits, internal defects from lurbinectedin exposure included cardiac defects.
Not present in the provided label excerpts.
In rats and rabbits, internal defects from lurbinectedin exposure included kidney agenesis.
Not present in the provided label excerpts.
In rats and rabbits, internal defects from lurbinectedin exposure included reduced lung development.
Not present in the provided label excerpts.
In rats and rabbits, fetal weights dropped with lurbinectedin exposure.
Not present in the provided label excerpts.
In rats and rabbits, ossification delays appeared across multiple bones with lurbinectedin exposure.
Not present in the provided label excerpts.
The FDA label for lurbinectedin includes a boxed warning.
Boxed-warning status cannot be verified from the provided label excerpts.
Lurbinectedin disrupts rapidly dividing cells.
The provided label text describes perturbation of the cell cycle and eventual cell death, but does not use the specific phrase 'rapidly dividing cells.'
Any exposure around conception or early pregnancy risks permanent structural damage.
Provided label excerpts do not state 'permanent structural damage' or specify conception/early pregnancy timing in that way.
Exposure during the first trimester of pregnancy to lurbinectedin gives rise to major malformations or loss of pregnancy.
Provided label excerpts do not give trimester-specific human outcomes or explicitly state 'first trimester' major malformations.
Exposure during later stages of pregnancy to lurbinectedin affects growth and development.
Not present in the provided label excerpts.
Patients who become pregnant while on lurbinectedin should stop the drug immediately.
The provided label excerpts advise counseling/contraception but do not include an explicit instruction to 'stop immediately.'
Patients who become pregnant while on lurbinectedin should seek immediate prenatal care.
Not present in the provided label excerpts.
Contradictions
Important Omissions
Whether the label contains a boxed warning (and if so, the exact boxed-warning language) was not verifiably addressed; the response stated it exists without label-text confirmation.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Unverified boxed-warning existence plus multiple unverified/detailed pregnancy teratogenicity claims and pregnancy-management directives (stop drug immediately; immediate prenatal care) reduce label fidelity and could mislead clinical decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Boxed-warning status and multiple pregnancy/teratogenicity details are not verifiable from the provided label excerpts; pregnancy action-step directives are also unverified.
Suggested Improvement
Restrict pregnancy-related statements to what is explicitly supported by provided label text (fetal harm/embryolethality in animals; counseling to use effective contraception with specified durations; pregnancy status verification). Remove or rephrase detailed malformation and trimester-specific claims unless the corresponding label text is provided.